Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- MTPC Applies for MP-424 in Japan
February 7, 2011
- Takeda Begins PIII Trial of AMG 386 in Japan
February 7, 2011
- MTPC Shipped 4 Injectables without Conducting Necessary Quality Tests
February 7, 2011
- Novartis Applies for Canakinumab for CAPS
February 7, 2011
- Insight Obtained into Mechanism of Nerve Cell Protection Following Cerebral Infarction
February 7, 2011
- Top-4 Wholesalers Report Slow Price Settlement, Difficulty in Reducing Yakkasa
February 7, 2011
- Eisai Won't Seek Regulatory Approval for Eritoran in March
February 7, 2011
- Peretinoin Reduces Risk of HCC Recurrence or Death
February 7, 2011
- JACDS Calls on Its Members to Refrain from Offering Points for Dispensing Services
February 7, 2011
- Otsuka Applies for New Indication of Bipolar Disorder for Abilify
February 7, 2011
- Kyowa Kirin Confirms Efficacy of KW-6500 for PD in PIII
February 7, 2011
- Torii Licenses Allergy Immunotherapy Products from ALK
February 7, 2011
- Chugai Seeks Additional Indication for Pegasys
February 7, 2011
- Erbitux plus FOLFOX Prolongs OS: Merck Serono
February 7, 2011
- Januvia Posts Sales of ¥10 Bil. in 2010: MSD
February 7, 2011
- Larger Doses Approved for Acetaminophen in Adults: Showa Yakuhin Kako
February 7, 2011
- The Customer Is KING
February 7, 2011
- Yakult Honsha Aims at Sales of ¥500 Bil. in FY2020
February 7, 2011
- Eisai Applies for Perampanel in the US, Europe
February 7, 2011
- 6-Month Data from PI/II Trial of Collategene Published
February 7, 2011
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…